Market Intelligence, Clinical Progress, and High-Purity Reagents for TAM-Targeted Oncology & Immunology.
Target Biology & Genetic Variants
CSF1R (colony-stimulating factor 1 receptor) is a class III receptor tyrosine kinase containing three Ig-like C2-type domains (UniProt P07333). Key genetic variants include rs56048668 (dbSNP), BANDDOS (impairs JNK phosphorylation upon CSF1 stimulation), and rs41338945. These mutations are critical for understanding drug resistance mechanisms and patient stratification.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CSF1R drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSF1R ECD-Fc / Kinase Domain Mutant Protein | |
| High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CSF1R Products | |
| Gene Delivery | CSF1R Lentivirus Premade Particles | |
| Full-length ORF for stable cell line construction. Ideal for internalization & signaling assays. | View CSF1R Products | |
| Benchmark Ab | Anti-CSF1R (Sequence of Cabiralizumab or Emactuzumab) | |
| Recombinant positive control for binding affinity standardization. | View CSF1R Products | |
| Validator | CSF1R siRNA Set | |
| For knockdown verification and assay specificity controls. | View CSF1R Products | |
| Related Target: CSF1 | CSF1 (M-CSF) Ligand | |
| Primary ligand for receptor binding competition & functional activation. | View CSF1 Products | |
| Related Target: IL34 | IL-34 | |
| Alternative ligand; critical for ligand-selective drug design & biased signaling studies. | View IL34 Products | |
| Related Target: PD-1 | PD-1 | |
| Synergistic pathway for tumor-associated macrophage (TAM) combination therapies. | View PD-1 Products | |
| Related Target: PDGFRB | PDGFRB | |
| Off-target safety counter-screening (kinase selectivity panel for small molecules/bispecifics). | View PDGFRB Products |
| Critical Assay Challenge | The TarMart Advantage |
|---|---|
| Ligand Blocking Validation (CSF1 vs IL34) | Native glycosylation (HEK293) ensures accurate tertiary structure for complex dual-ligand SPR binding assays. |
| Cross-species Translation (Cyno/Mouse) | Human, Mouse, and Cyno ortholog CSF1R ECD proteins available with >95% purity; sequence verified by mass spec. |
| Internalization Efficiency Quantification (ADC development) | CSF1R-Lentivirus stable cell lines preserve native conformation for accurate pH-sensitive dye internalization assays. |
| PDGFR Subfamily Counter-Screening (Off-target toxicity) | Homolog panel proteins (PDGFRA, PDGFRB, KIT) strictly verified; available for selectivity assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives in Screening | Validated siRNA included for target-specificity verification. |
Live CSF1R R&D Tracker
Global Clinical Landscape & Future Outlook
The race for CSF1R therapeutics is intensifying, with major players shifting focus from traditional mAbs to highly selective small molecules, ADCs, and bispecific constructs. First-generation inhibitors (Pexidartinib) have established clinical proof-of-concept in tenosynovial giant cell tumors (TGCT), but face toxicity hurdles (hepatotoxicity, black-box warning). The next wave targets solid tumor microenvironment modulation through Tumor-Associated Macrophage (TAM) reprogramming and combination regimens with checkpoint inhibitors. Antibody-based modalities (ADCs, bispecifics) aim to reduce systemic toxicity by localizing macrophage depletion within the tumor. Combination therapies, particularly pairing CSF1R blockade with immune checkpoint inhibitors, remain a dominant strategy for refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Daiichi Sankyo, Deciphera, Johnson & Johnson | TGCT, Solid Tumors, Rheumatoid Arthritis | Selectivity Assay (Need Kinase Domain Mutant vs WT Proteins & PDGFR/KIT counter-screening) |
| Monoclonal Antibody (Neutralizing) | Roche (Emactuzumab), BMS (Cabiralizumab), Syndax | Oncology, cGVHD, Fibrosis | Ligand Competition Assay (Need high-purity ECD-Fc & CSF1/IL34 proteins) |
| ADC | AstraZeneca, Bristol Myers Squibb | Solid Tumors (PDAC, Ovarian) | Internalization Assay (Need high-purity CSF1R ECD-Fc for conjugation optimization, Lentivirus cell lines) |
| Bispecific (CSF1R x PD-1) | Macrogenics, Novartis | Immunotherapy combos | Heterodimer Validation (Need cross-reactive Abs against human/cyno epitopes) |
Molecular Differentiation & Assay Strategy
To achieve best-in-class CSF1R-targeted drugs, developers must address the following parameters:
- Affinity: Moderate affinity (Kd ~0.1-1 nM) is preferred for solid tumors to avoid peripheral sink effect. SPR/BLI assays with CSF1 and IL34 ligands at acidic pH simulate tumor microenvironment.
- Mechanism (Dual-ligand blockade): Antibodies must compete both CSF1 and IL34 binding. Ternary complex competition assay (ELISA or SPR) using high-quality ECD-Fc and ligands.
- Internalization Rate: Critical for ADC development. Use CSF1R-Lentivirus stable cell lines and pH-sensitive dye (pHrodo) assays.
- Cross-species Reactivity: Preclinical tox requires human/cyno/mouse cross-reactive reagents. TarMart provides ortholog triple set with mass spec verification.
- Selectivity over PDGFR Family: Off-target counter-screening panel (PDGFRB, PDGFRA, KIT) is essential for small molecules and bispecifics.
- Ligand Bias: Selective blockade of IL-34 (tumor-derived) while sparing CSF1 (hematopoietic) can reduce toxicity. Dual-ligand proteins enable differentiated blocking studies.
TarMart supports each need with high-purity HEK293-expressed proteins, validated siRNA, and lentiviral particles.
Related Targets & Cross-Selling Opportunities
- CSF1 / IL34: Essential ligands for competitive binding assays.
- PD-1 / PD-L1: Immune checkpoint synergy; required for IO combo efficacy models.
- PDGFRB / KIT: Off-target safety controls for small molecule programs.
- CCR2 / CD47: Emerging compensatory/resistance pathways in TAM modulation; future combo kit expansion.